The remarkable conformational plasticity of alpha-synuclein: Blessing or curse?

Trends in Molecular Medicine

Volumn 19, Issue 6, 2013, Pages 368-377

  Deleersnijder, Angélique ^a   Gerard, Melanie ^a   Debyser, Zeger ^b   Baekelandt, Veerle ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CALCIUM ION; CATECHOL METHYLTRANSFERASE INHIBITOR; CUPROUS ION; FERRIC ION; FK 506 BINDING PROTEIN; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

AMINO ACID SEQUENCE; CONFORMATIONAL TRANSITION; DISEASE COURSE; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; GENE DUPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GOLGI COMPLEX; HEREDITY; HUMAN; IN VITRO STUDY; LIPID MEMBRANE; MISSENSE MUTATION; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NITRATION; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PATHOGENESIS; PATHOGENICITY; PLASTICITY; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; REVIEW; SUMOYLATION; SYNAPTOSOME; UBIQUITINATION; UPREGULATION; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; TOXICITY;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; PARKINSON DISEASE; PROTEIN CONFORMATION;

EID: 84878582896     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.04.002     Document Type: Review

References (110)

1. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
2. Venda L.L., et al. Alpha-synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010, 33:559-568.
3. Nalls M.A., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
4. Low K., Aebischer P. Use of viral vectors to create animal models for Parkinson's disease. Neurobiol. Dis. 2012, 48:189-201.
5. Whitworth A.J. Drosophila models of Parkinson's disease. Adv. Genet. 2011, 73:1-50.
6. Crabtree D.M., Zhang J. Genetically engineered mouse models of Parkinson's disease. Brain Res. Bull. 2012, 88:13-32.
7. Kordower J.H., et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
8. Li J.Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
9. Mendez I., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 2008, 14:507-509.
10. Desplats P., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13010-13015.
11. Hansen C., et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
12. Masuda-Suzukake M., et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013, 10.1093/brain/awt037.
13. Luk K.C., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
14. Danzer K.M., et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 2012, 7:42.
15. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
16. Goedert M., et al. 100 years of Lewy pathology. Nat. Rev. Neurol. 2013, 9:13-24.
17. Del Tredici K., Braak H. Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol. 2012, 124:643-664.
18. Uversky V.N. Intrinsically disordered proteins from A to Z. Int. J. Biochem. Cell Biol. 2011, 43:1090-1103.
19. Dedmon M.M., et al. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc. 2005, 127:476-477.
20. Bertoncini C.W., et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1430-1435.
21. Breydo L., et al. Alpha-synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 2012, 1822:261-285.
22. Bellani S., et al. The regulation of synaptic function by alpha-synuclein. Commun. Integr. Biol. 2010, 3:106-109.
23. Abeliovich A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
24. Murphy D.D., et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20:3214-3220.
25. Yavich L., et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 2005, 20:303-313.
26. Larsen K.E., et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 2006, 26:11915-11922.
27. Perlmutter J.D., et al. Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. J. Biol. Chem. 2009, 284:7177-7189.
28. Chandra S., et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
29. Burré J., et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
30. Perez R.G., et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22:3090-3099.
31. Peng X., et al. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell Sci. 2005, 118:3523-3530.
32. Tehranian R., et al. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J. Neurochem. 2006, 99:1188-1196.
33. Cooper A.A., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
34. Quilty M.C., et al. Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp. Neurol. 2006, 199:249-256.
35. Dettmer U., et al. In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J. Biol. Chem. 2013, 288:6371-6385.
36. Bartels T., et al. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
37. Wang W., et al. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17797-17802.
38. Fauvet B., et al. Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J. Biol. Chem. 2012, 287:15345-15364.
39. Binolfi A., et al. Bacterial in-cell NMR of human alpha-synuclein: a disordered monomer by nature?. Biochem. Soc. Trans. 2012, 40:950-954.
40. Binolfi A., et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J. Am. Chem. Soc. 2006, 128:9893-9901.
41. Binolfi A., et al. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. J. Am. Chem. Soc. 2008, 130:11801-11812.
42. Davies P., et al. Alpha-synuclein is a cellular ferrireductase. PLoS ONE 2011, 6:e15814.
43. Caudle W.M., et al. Industrial toxicants and Parkinson's disease. Neurotoxicology 2012, 33:178-188.
44. Noyce A.J., et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 2012, 72:893-901.
45. Uversky V.N., et al. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology 2002, 23:527-536.
46. Lee H.J., et al. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 2002, 277:5411-5417.
47. Sherer T.B., et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 2002, 22:7006-7015.
48. Betarbet R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
49. Manning-Bog A.B., et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277:1641-1644.
50. Norris E.H., et al. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am. J. Pathol. 2007, 170:658-666.
51. Wills J., et al. Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLoS ONE 2012, 7:e30745.
52. Middleton E.R., Rhoades E. Effects of curvature and composition on alpha-synuclein binding to lipid vesicles. Biophys. J. 2010, 99:2279-2288.
53. Varkey J., et al. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J. Biol. Chem. 2010, 285:32486-32493.
54. Westphal C.H., Chandra S.S. Monomeric synucleins generate membrane curvature. J. Biol. Chem. 2013, 288:1829-1840.
55. Beyer K. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem. Biophys. 2007, 47:285-299.
56. Dikiy I., Eliezer D. Folding and misfolding of alpha-synuclein on membranes. Biochim. Biophys. Acta 2011, 1818:1013-1018.
57. Hogen T., et al. Two different binding modes of alpha-synuclein to lipid vesicles depending on its aggregation state. Biophys. J. 2012, 102:1646-1655.
58. Kiely A.P., et al. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 2013, 10.1007/s00401-013-1096-7.
59. Appel-Cresswell S., et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 2013, 10.1002/mds.25421.
60. Maraganore D.M., et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006, 296:661-670.
61. Greenbaum E.A., et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 2005, 280:7800-7807.
62. Li J., et al. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 2001, 40:11604-11613.
63. Rospigliosi C.C., et al. E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. J. Mol. Biol. 2009, 388:1022-1032.
64. McClendon S., et al. Charge neutralization and collapse of the C-terminal tail of alpha-synuclein at low pH. Protein Sci. 2009, 18:1531-1540.
65. Braithwaite S.P., et al. alpha-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev. Neurosci. 2012, 23:191-198.
66. Beyer K., Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol. Neurobiol. 2013, 47:509-524.
67. Siman P., Brik A. Chemical and semisynthesis of posttranslationally modified proteins. Org. Biomol. Chem. 2012, 10:5684-5697.
68. Hejjaoui M., et al. Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: alpha-synuclein phosphorylation at tyrosine 125. J. Am. Chem. Soc. 2012, 134:5196-5210.
69. Hashimoto M., et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther. 2004, 11:1713-1723.
70. Shaltiel-Karyo R., et al. Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS ONE 2010, 5:e13863.
71. Gerard M., et al. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J. 2006, 20:524-526.
72. Gerard M., et al. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J. Neurosci. 2010, 30:2454-2463.
73. Deleersnijder A., et al. Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of α-synuclein aggregation. J. Biol. Chem. 2011, 286:26687-26701.
74. Meuvis J., et al. The conformation and the aggregation kinetics of alpha-synuclein depend on the proline residues in its C-terminal region. Biochemistry 2010, 49:9345-9352.
75. Petrucelli L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36:1007-1019.
76. Zach S., et al. Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture. Cell. Mol. Neurobiol. 2007, 27:505-515.
77. Zhou W., et al. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 2000, 866:33-43.
78. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
79. Kirik D., et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2884-2889.
80. Klein R.L., et al. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 2002, 13:605-612.
81. Lauwers E., et al. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 2003, 13:364-372.
82. Lo Bianco C., et al. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10813-10818.
83. Lauwers E., et al. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol. Aging 2007, 28:248-257.
84. Greffard S., et al. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol. Aging 2010, 31:99-103.
85. Masliah E., et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
86. Karpinar D.P., et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 2009, 28:3256-3268.
87. Winner B., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4194-4199.
88. Burré J., et al. Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci. 2012, 32:15227-15242.
89. Kostka M., et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J. Biol. Chem. 2008, 283:10992-11003.
90. van Rooijen B.D., et al. Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism. PLoS ONE 2010, 5:e14292.
91. Reynolds N.P., et al. Mechanism of membrane interaction and disruption by alpha-synuclein. J. Am. Chem. Soc. 2011, 133:19366-19375.
92. Sultana Z., et al. Dynamic modeling of alpha-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy. Neuroscience 2011, 199:303-317.
93. Masliah E., et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 2011, 6:e19338.
94. Schneeberger A., et al. Vaccination for Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S11-S13.
95. Mounsey R.B., Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int. J. Cell Biol. 2012, 2012:983245.
96. Braithwaite S.P., et al. Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease. Neurochem. Int. 2012, 61:899-906.
97. Lamberto G.R., et al. Toward the discovery of effective polycyclic inhibitors of alpha-synuclein amyloid assembly. J. Biol. Chem. 2011, 286:32036-32044.
98. Bieschke J., et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7710-7715.
99. Huggins K.N., et al. Designed hairpin peptides interfere with amyloidogenesis pathways: fibril formation and cytotoxicity inhibition, interception of the preamyloid state. Biochemistry 2011, 50:8202-8212.
100. Perchiacca J.M., et al. Structure-based design of conformation- and sequence-specific antibodies against amyloid beta. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:84-89.
101. Ladiwala A.R., et al. Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:19965-19970.
102. Putcha P., et al. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 2010, 332:849-857.
103. Bahr B.A., et al. Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases. Rejuvenation Res. 2012, 15:189-197.
104. Beyer K., Ariza A. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. Curr. Med. Chem. 2008, 15:2748-2759.
105. Davidson W.S., et al. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273:9443-9449.
106. Koo H.J., et al. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants. Biochem. Biophys. Res. Commun. 2009, 386:165-169.
107. Hoyer W., et al. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 2004, 43:16233-16242.
108. Wood S.J., et al. alpha-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 1999, 274:19509-19512.
109. Knowles T.P., et al. An analytical solution to the kinetics of breakable filament assembly. Science 2009, 326:1533-1537.
110. Cremades N., et al. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 2012, 149:1048-1059.